FT

Bristol-Myers Squibb to buy heart treatment maker for $13.1bn

MyoKardia deal is US company’s first major acquisition since Celgene last year

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button